Furthermore, a recent study revealed that E2F6 can be deubiquitinated and stabilized by USP22 and thereby inhibit the transcription of DUSP1, which in turn activates AKT signalling and leads to HCC progression 47. Here, USP22 is linked to hepatocellular carcinoma.